Cargando…

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease

OBJECTIVES: Interleukin-23 (IL-23) has emerged as a new therapeutic target for the treatment of inflammatory bowel disease (IBD). As biomarkers of disease state and treatment efficacy are becoming increasingly important in drug development, we sought to identify efficacy biomarkers for anti-IL-23 th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cayatte, Corinne, Joyce-Shaikh, Barbara, Vega, Felix, Boniface, Katia, Grein, Jeffrey, Murphy, Erin, Blumenschein, Wendy M, Chen, Smiley, Malinao, Maria-Christina, Basham, Beth, Pierce, Robert H, Bowman, Edward P, McKenzie, Brent S, Elson, Charles O, Faubion, William A, Malefyt, Rene de Waal, Kastelein, Robert A, Cua, Daniel, McClanahan, Terrill K, Beaumont, Maribel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365674/ https://www.ncbi.nlm.nih.gov/pubmed/23238132 http://dx.doi.org/10.1038/ctg.2012.2

Ejemplares similares

Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling
por: Boniface, Katia, et al.
Publicado: (2009)

Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation
por: Kleinschek, Melanie A., et al.
Publicado: (2009)

Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Biomarkers of Disease and Treatment in Murine and Cynomolgus Models of Chronic Asthma
por: Louten, Jennifer, et al.
Publicado: (2012)

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
por: Langrish, Claire L., et al.
Publicado: (2005)

Polygenic risk score predicts risk of primary sclerosing cholangitis in inflammatory bowel disease
por: Wang, Ming-Hsi, et al.
Publicado: (2023)

Genital warts and inflammatory bowel diseases: Danish real‐world evidence to assess patient‐relevant outcomes
por: McLellan, Paul, et al.
Publicado: (2022)

Perianal fistulizing Crohn's disease and overall risk of cancer: No red flag
por: McLellan, Paul, et al.
Publicado: (2023)

Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol
por: Mc Gettigan, Neasa, et al.
Publicado: (2022)

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
por: Alrashed, Fatema, et al.
Publicado: (2021)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis
por: Hillyer, Philippa, et al.
Publicado: (2009)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

Crohn’s disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial
por: Raman, Maitreyi, et al.
Publicado: (2022)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis
por: Brookes, Matthew J, et al.
Publicado: (2020)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study
por: Murthy, Sanjay K, et al.
Publicado: (2020)

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
por: Mayer, Lloyd, et al.
Publicado: (2014)

Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)
por: Sheridan, Juliette, et al.
Publicado: (2018)

Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation
por: Murphy, Craig A., et al.
Publicado: (2003)

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
por: Schmitt, Heike, et al.
Publicado: (2019)

A blood-based prognostic biomarker in IBD
por: Biasci, Daniele, et al.
Publicado: (2019)

High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning
por: McDonnell, Martin, et al.
Publicado: (2020)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease
por: Häsler, Robert, et al.
Publicado: (2017)

Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis
por: Masterson, Joanne C, et al.
Publicado: (2015)

In vivo identification of novel STAT5 target genes
por: Basham, Beth, et al.
Publicado: (2008)

BSG 2024 IBD guidelines protocol (standard operating procedures)
por: Gordon, Morris, et al.
Publicado: (2023)

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial
por: Münch, Andreas, et al.
Publicado: (2016)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease
por: Kutschera, Maximilian, et al.
Publicado: (2021)

SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation
por: Južnić, Lea, et al.
Publicado: (2021)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Evolutionary history of human colitis-associated colorectal cancer
por: Baker, Ann-Marie, et al.
Publicado: (2019)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_rmipj419m3c0qnsfprrckga7hk